



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

The survival times of malaria-infected mice are prolonged more by several new two-carbon-linked artemisinin-derived dimer carbamates than by the trioxane antimalarial drug artemether



Ryan C. Conyers^a, Jennifer R. Mazzone^a, Maxime A. Siegler^a, Abhai K. Tripathi^{b,c}, David J. Sullivan^{b,c}, Bryan T. Mott^a, Gary H. Posner^{a,c,*}

^a Department of Chemistry, School of Arts and Sciences, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States

^b W. Harry Feinstone Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, MD 21205, United States

^c The Johns Hopkins Malaria Research Institute, Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, MD 21205, United States

ARTICLE INFO

Article history:

Received 17 December 2013

Revised 13 January 2014

Accepted 21 January 2014

Available online 30 January 2014

Keywords:

Antimalarial chemotherapy

Trioxane dimer carbamates

Single oral dose ACT

Oral bioavailability

ABSTRACT

Sixteen new artemisinin-derived 2-carbon-linked trioxane dimers were prepared to study chemical structure/antimalarial activity relationships (SAR). Administering a very low single oral dose of only 5 mg/kg of dimer secondary alcohol **6a** or **6b** plus 15 mg/kg of mefloquine hydrochloride prolonged the lives of *Plasmodium berghei*-infected mice to an average of 25 days after infection. This ACT chemotherapy result is of high medicinal significance because the antimalarial efficacy of the popular trioxane drug artemether (**2**) plus mefloquine under the same conditions was significantly lower (only 20 day average survival). NH-aryl carbamate derivatives **7e**, **7i**, and **7j** of 2-carbon-linked dimer alcohol **6b** also significantly outperformed artemether (**2**) in prolonging the survival times (25–27 days) of malaria-infected mice.

© 2014 Elsevier Ltd. All rights reserved.

Malaria remains a devastating infectious disease, especially in tropical and sub-tropical areas of the world. Attempts at developing vaccines to protect humans from contracting malaria have been only partially successful.¹ Therefore, safe and effective chemotherapy to cure malaria-infected patients is desperately needed. With widespread resistance of *Plasmodium falciparum* malaria parasites to such previously reliable antimalarial drugs like chloroquine,^{2–4} antimalarial drugs with new mechanism(s) of action are valuable for chemotherapy of malaria patients.^{5,6} In recent years, a dramatic advance has been made with the use of the trioxane artemisinin (**1**) and its derivatives artemether (**2**) and sodium artesunate (**3**, Fig. 1) as fast-acting and highly efficacious antimalarials.^{7,8} Combining such fast-acting but short lived trioxanes with known slower-acting but longer-lived nitrogen-containing compounds like mefloquine or lumefantrine is now recommended as standard operating procedure by the World Health Organization (WHO).⁹ Such artemisinin combination therapy (ACT) has led to several combinations that are now readily available as over-the-counter drugs. These commercial ACTs, however, typically require multiple dosing for several days in order to achieve full cures.^{10–18}

Compliance with such a regimen is often problematic. Therefore, a single dose cure is becoming a major goal in modern antimalarial chemotherapy.^{19–24} We have recently designed, synthesized, and biologically evaluated a series of new C-10 carbon-linked trioxane dimers some of which completely cure malaria-infected mice using one single-digit oral dose of trioxane along with a non-trioxane drug.^{25–29} Artemisinin-derived C-10 carbon-linked dimers having linking units of five,²⁶ four,²⁷ and three^{28,29} carbon atoms as well as dimers with structurally distinct linking units^{30–32} having potent antimalarial activity have been reported. Recently we described preparation of artemisinin-derived 2-carbon-linked dimer ketone **4** (36% overall yield from artemisinin) and of its corresponding curative oxime derivatives **5**.²⁵ We have now discovered that 2-carbon-linked dimer ketone **4** can be reduced with very high stereocontrol predominantly into secondary alcohol diastereomer **6b**. The new chemical entity alcohol **6b** was easily transformed in one step into a series of fourteen NH-aryl carbamates **7** some of which are more efficacious than the popular monomeric trioxane drug artemether (**2**) in prolonging the survival times of malaria-infected mice (Scheme 1).

It was important to explore the utility of this new 2-carbon-linked dimer scaffold by performing a number of functional group transformations. The dimer ketone **4** was reduced into a pair of diastereomeric alcohols **6a** and **6b** that were easily separable on

Abbreviations: SAR, structure–activity relationship; ACT, artemisinin combination therapy; DIBALH, diisobutylaluminum hydride.

* Corresponding author. Tel.: +1 410 516 4670.

E-mail address: ghp@jhu.edu (G.H. Posner).




Figure 1. Artemisinin and first generation derivatives.

silica gel (Scheme 2). Surprisingly, even with a bulky reducing agent such as diisobutylaluminum hydride (DIBALH), the alcohols **6a** and **6b** were obtained in a 1:1 ratio. However, treatment with commercially available enantiopure (*R*)-CBS-oxazaborolidine³³ **8a** and borane in tetrahydrofuran (BH₃·THF) achieved highly stereoselective reduction of the ketone (98% diastereomeric excess, as determined by ¹H NMR of the crude reaction mixture), allowing direct access to diastereomer **6b**. Employing the enantiomeric (*S*)-CBS oxazaborolidine **8b** did not afford the same selectivity, forming both alcohol products **6a** and **6b** in a 62:48 ratio under these conditions.


The more polar alcohol (by analytical TLC) was hypothesized to be the (*S*)-isomer **6b** based on analysis of the proton NMR signals (Fig. 2), on the expected product from the known mechanism of this reaction,³⁴ and on the structural configuration by molecular model. In the (*S*)-isomer, the alcohol points toward the C5 proton, facilitating a deshielding interaction with this proton (Fig. 2III). Furthermore, the C10 proton would be locked into a pseudo equatorial-axial conformation with the C17 proton (looking down the C10–C17 bond), resulting in a smaller coupling constant (Fig. 2IV). Conversely, the alcohol would be pointed away from the C5 proton in the (*R*)-isomer (Fig. 2I), and the C10–C17 protons would be in a pseudo trans-diaxial orientation (Fig. 2II). Indeed this trend is seen in the ¹H NMR. Crystals of **6b** were obtained via slow evaporation of a mixed solvent system (1:4 mixture of dichloromethane and hexanes, with several drops of benzene added). X-ray structure determination confirms the stereochemistry as described in Figure 3. The crystal structure (Fig. 3) also revealed interesting structural characteristics when compared with the ketone precursor.²⁵ The ketone is a rigid, cage-like structure that locked the endoperoxide pharmacophore on the outside of the molecule, and it was hypothesized that this would be beneficial for antima-

larial activity. Reduction to the alcohol seems to contort the six-membered glycosidic ring of the artemisinin core into a twisted conformation. The endoperoxides are also facing in, though flexibility in solution would still be expected.


The major diastereomeric alcohol **6b** was converted easily in one step using commercial aryl isocyanates into a series of fourteen NH-aryl carbamates **7** which include phenyl, monofluoro, difluoro, trifluoro, monochloro, monobromo, cyano, and nitro derivatives (Fig. 4). Attempts at preparing NH-alkyl carbamates using commercial alkyl isocyanates were unsuccessful.

Our recent experience showed that all of the new 2-carbon-linked dimer oxime NH-aryl carbamates **5** had significant *in vivo* antimalarial efficacy.²⁵ Therefore, we proceeded directly with *in vivo* efficacy evaluation of the new series of OC(O)NH-aryl carbamates **7**. Indeed, as expected, all of these carbamates **7** had significant chemotherapeutic value, with some outperforming the trioxane antimalarial drug artemether (**2**).

To each two-carbon-linked dimer alcohols **6a** and **6b** and carbamates **7** (0.60 mg), 113 μ L of 7:3 Tween 80/ethanol with mefloquine hydrochloride (1.80 mg) was added and then diluted with 1087 μ L of deionized water for oral administration to 5-week old C57BL/6J male mice (from Jackson Laboratory) weighing about 20 g that were infected with *Plasmodium berghei* ANKA strain (2×10^7 parasitized erythrocytes). Each of four mice in a group was treated orally 24 h post-infection with a single dose of 200 μ L of diluted compound solution, corresponding to a dose of 5 mg/kg trioxane combined with 15 mg/kg of mefloquine hydrochloride. Determining blood parasitemia levels and monitoring the duration of animal survival compared to survival time of animals receiving no drug are both widely accepted as measures of a drug's antimalarial efficacy. An average of 9.8% parasitemia was observed in the control (infected but no drug treatment) group



Scheme 1. Two-carbon-linked dimer derivatives.



a) DIBALH, CH₂Cl₂, -78 °C; 98% b) **8b**, BH₃·THF, 0 °C -rt, 99% overall yield for both diastereomers; c) **8a**, BH₃·THF, 0 °C -rt, 92%

Scheme 2. Two-carbon-linked dimer alcohols **6**.

Download English Version:

<https://daneshyari.com/en/article/1369894>

Download Persian Version:

<https://daneshyari.com/article/1369894>

[Daneshyari.com](https://daneshyari.com)